NASDAQ:BLFS - BioLife Solutions Stock Price, Forecast & News

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

BioLife Solutions Inc (NASDAQ:BLFS) announced its quarterly earnings data on Thursday, August, 9th. The medical equipment provider reported $0.05 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.01. The medical equipment provider had revenue of $5.18 million for the quarter, compared to the consensus estimate of $5.20 million. BioLife Solutions had a net margin of 46.77% and a return on equity of 5.37%. View BioLife Solutions' Earnings History.

BioLife Solutions is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for BioLife Solutions.

BioLife Solutions will be holding an earnings conference call on Wednesday, March 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

BioLife Solutions updated its FY 2020 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$50-56 million, compared to the consensus revenue estimate of $$42.95 million.

7 analysts have issued 12 month price objectives for BioLife Solutions' shares. Their forecasts range from $22.00 to $27.00. On average, they anticipate BioLife Solutions' stock price to reach $24.29 in the next year. This suggests a possible upside of 55.4% from the stock's current price. View Analyst Price Targets for BioLife Solutions.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioLife Solutions.

News stories about BLFS stock have been trending very negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. BioLife Solutions earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for BioLife Solutions.

Some companies that are related to BioLife Solutions include InMode (INMD), Natus Medical (NTUS), AxoGen (AXGN), TransMedics Group (TMDX), Zynex (ZYXI), Cutera (CUTR), Semler Scientific (SMLR), Viewray (VRAY), Stereotaxis (STXS), Rockwell Medical (RMTI), Soleno Therapeutics (SLNO), Fonar (FONR), Edap Tms (EDAP), BioSig Technologies (BSGM) and Second Sight Medical Products (EYES).

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Canopy Growth (CGC), AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Square (SQ), Twilio (TWLO), Amarin (AMRN), Cara Therapeutics (CARA), Applied Materials (AMAT) and Advanced Micro Devices (AMD).

BioLife Solutions' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Casdin Capital LLC (12.07%), Russell Investments Group Ltd. (2.72%), Driehaus Capital Management LLC (2.33%), Royce & Associates LP (1.08%), Essex Investment Management Co. LLC (1.04%) and Parkman Healthcare Partners LLC (0.81%). Company insiders that own BioLife Solutions stock include Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger. View Institutional Ownership Trends for BioLife Solutions.

BLFS stock was sold by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., Cadence Capital Management LLC, Schonfeld Strategic Advisors LLC, Perkins Capital Management Inc., Russell Investments Group Ltd., Driehaus Capital Management LLC, Bank of America Corp DE and Penbrook Management LLC. Company insiders that have sold BioLife Solutions company stock in the last year include Andrew G Hinson, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Michael Rice, Raymond W Cohen, Todd Berard and Walter Villiger. View Insider Buying and Selling for BioLife Solutions.

BLFS stock was bought by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Roubaix Capital LLC, Marshall Wace LLP, Bank of Montreal Can, Casdin Capital LLC, Isthmus Partners LLC, Goldman Sachs Group Inc. and Franklin Resources Inc.. View Insider Buying and Selling for BioLife Solutions.

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BLFS stock can currently be purchased for approximately $15.63.

BioLife Solutions has a market capitalization of $319.63 million and generates $19.74 million in revenue each year. The medical equipment provider earns $3.27 million in net income (profit) each year or $0.14 on an earnings per share basis. BioLife Solutions employs 54 workers across the globe.View Additional Information About BioLife Solutions.

The official website for BioLife Solutions is http://www.biolifesolutions.com/.

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]